Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Multiple system atrophy - Pathophysiology and management
Autore:
Wenning, GK; Braune, S;
Indirizzi:
Univ Innsbruck Hosp, Dept Neurol, A-6020 Innsbruck, Austria Univ InnsbruckHosp Innsbruck Austria A-6020 , A-6020 Innsbruck, Austria Univ Hosp, Dept Neurol, Freiburg, Germany Univ Hosp Freiburg GermanyUniv Hosp, Dept Neurol, Freiburg, Germany
Titolo Testata:
CNS DRUGS
fascicolo: 11, volume: 15, anno: 2001,
pagine: 839 - 852
SICI:
1172-7047(2001)15:11<839:MSA-PA>2.0.ZU;2-7
Fonte:
ISI
Lingua:
ENG
Soggetto:
PROGRESSIVE SUPRANUCLEAR PALSY; IDIOPATHIC PARKINSONS-DISEASE; GLIAL CYTOPLASMIC INCLUSIONS; NEUROGENIC ORTHOSTATIC HYPOTENSION; POSITRON EMISSION TOMOGRAPHY; EXTERNAL ANAL-SPHINCTER; METAIODOBENZYLGUANIDINE MYOCARDIAL SCINTIGRAPHY; MAGNETIC-RESONANCE SPECTROSCOPY; RICHARDSON-OLSZEWSKI-SYNDROME; CHRONIC AUTONOMIC FAILURE;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
120
Recensione:
Indirizzi per estratti:
Indirizzo: Wenning, GK Univ Innsbruck Hosp, Dept Neurol, Anichstr 35, A-6020 Innsbruck, Austria Univ Innsbruck Hosp Anichstr 35 Innsbruck Austria A-6020 tria
Citazione:
G.K. Wenning e S. Braune, "Multiple system atrophy - Pathophysiology and management", CNS DRUGS, 15(11), 2001, pp. 839-852

Abstract

Multiple system atrophy (MSA) is a sporadic neurodegenerative disorder that usually manifests when ar individual is in his/her early fifties and progresses relentlessly with a mean survival of 9 years. Clinically, MSA is dominated by autonomic/urogenital failure which may be associated with either parkinsonism (MSA-P subtype) in 80% of cases or with cerebellar ataxia (MSA-C subtype) in 20% of cases. Pathologically, MSA is characterised by a neuronal multisystem degeneration and abnormal glial cytoplasmic inclusions containing alpha -synuclein aggregates,Autonomic and urogenital features of MSA should be identified early on because they can be treated effectively in many instances. In contrast, pharmacological treatment of motor features is often disappointing, except for a minority of patients with MSA-P who derive transient benefit from levodopa treatment. In the future, neurotransplantation may extend or improve the treatment response in MSA-P, but further preclinical evidence is required prior to clinical application. Neuroprotection strategies may slow down disease progression in MSA and the results of the first double-blind trial of riluzole (an inhibitor of glutamate release) in patients with MSA will be available in 2004.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 19/01/20 alle ore 06:18:20